Skip to main content
Fig. 4 | BMC Neurology

Fig. 4

From: Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study

Fig. 4

Change in mean lymphocyte count during the core and extension study (extension safety population). EoS (end of study): in this instance is the last non-missing value up to 2 days after the last dose date and is summarized as last assessment on study drug. Data at 0.5 months (day 15) for fingolimod 0.5 mg (n = 54) and 1.25 mg (n = 56) represent values obtained during the core study (safety population)

Back to article page